Recent Advances in the Management of Adverse Events Associated with Lorlatinib
Dehua Liao,Jiwen Zhang,Ting Yan,Shanshan Chen,Wei Li,Dangang Shangguan,Zhihua She
DOI: https://doi.org/10.2147/ott.s426989
IF: 4
2023-09-06
OncoTargets and Therapy
Abstract:Dehua Liao, 1 Jiwen Zhang, 1, 2 Ting Yan, 1 Shanshan Chen, 1 Wei Li, 1 Dangang Shangguan, 1, &ast Zhihua She 3, &ast 1 Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China; 2 School of Pharmacy, University of South China, Hengyang, People's Republic of China; 3 Department of Medical Administration, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhihua She, Department of Medical Administration, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, People's Republic of China, Email Dangang Shangguan, Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China, Email As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other ALK-TKIs, lorlatinib has a unique safety profile for hyperlipidemia and central nervous system adverse events. Lorlatinib-induced adverse events are well tolerated, permanent discontinuations are rarely reported, and dose modifications and/or standard medical therapy are useful for the management of adverse events. Our present study reviews the safety profile of lorlatinib as well as the relevant management strategies. Our present study aims to provide a practical guide for the scientific management and application of lorlatinib. Keywords: ALK, lorlatinib, adverse event, NSCLC, therapy management Lung cancer is one of the most common types of cancer and has the highest cancer-related mortality worldwide, with a 5-year survival rate of only 10 to 20%. 1,2 Non-small cell lung cancer (NSCLC) accounts for 85% of all reported lung cancer cases. 3 Based on pathologic classification, NSCLC is further classified into three major subtypes: adenocarcinoma, squamous carcinoma and large cell carcinoma. 4 With the understanding of the molecular biology of NSCLC, numerous small molecular tyrosine kinase inhibitors (TKIs) have been successfully approved as targeted therapies in patients with oncogene-driven mutations, which are tremendous advances in NSCLC treatment. 5,6 In comparison with traditional platinum-based chemotherapy, TKIs significantly improved overall survival (OS) and quality of life in NSCLC patients with oncogenic driver mutations. 7 Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are the most common types of targetable driver mutations in NSCLC, which are generally mutually exclusive. Rearrangements of ALK are present in 5% of NSCLC patients, especially those with no or light smoking history, adenocarcinoma histology, younger age and female sex. 8 The approval of TKIs has revolutionized the prognosis and management of ALK-positive NSCLC. Currently, there are three generations of ALK-TKIs have been approved for the first-line and later treatment of ALK-positive NSCLC, such as the first generation of crizotinib, the second generation of alectinib, brigatinib, ceritinib, and ensartinib, the third generation of lorlatinib. The efficacy and safety of these TKIs have been widely explored in large-scale, multicenter, randomized controlled trials. As a novel, highly potent inhibitor of ALK, lorlatinib competitively binds to the adenosine triphosphate-binding pocket, blocking ALK-dependent oncogenic signaling (Figure 1). Previous studies have reported that lorlatinib exhibited anticancer effects in naïve ALK-positive NSCLC and those harboring mutations in ALK that conferred resistance to ALK inhibitors, including G1202R and I1171N mutations. 9,10 A remarkable molecular structure feature of lorlatinib is that it is macrocyclic, which distinguishes it from other first- and second-generation ALK-TKIs. 11 Furthermore, lorlatinib could effectively penetrate the blood-brain barrier in part by minimizing p-glycoprotein-1-mediated efflux, exhibiting highly effective treatment of those with CNS metastases. 9,12 Hence, lorlatinib was approved as a subsequent line therapy for ALK-positive advanced NSCLC in 2018 and was approved for use in the first-line setting in later days. 13,14 Figure 1 The anticancer mechanism of lorlatinib. As shown in previous clinical trials and real-world studies, -Abstract Truncated-
oncology,biotechnology & applied microbiology